These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 35305420)
1. Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. Chen S; Li X; Wang H; Chen G; Zhou Y Biochem Biophys Res Commun; 2022 May; 604():158-164. PubMed ID: 35305420 [TBL] [Abstract][Full Text] [Related]
2. HNRNPA2B1 stabilizes NFATC3 levels to potentiate its combined actions with FOSL1 to mediate vasculogenic mimicry in GBM cells. Wang H; Shi Y; Zhou X; Zhang L; Yang A; Zhou D; Ma T Cell Biol Toxicol; 2024 Jun; 40(1):44. PubMed ID: 38862832 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
7. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway. Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659 [TBL] [Abstract][Full Text] [Related]
8. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654 [TBL] [Abstract][Full Text] [Related]
9. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway. Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884 [TBL] [Abstract][Full Text] [Related]
10. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414 [TBL] [Abstract][Full Text] [Related]
11. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway. Niu G; Sun L; Pei Y; Wang D Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844 [TBL] [Abstract][Full Text] [Related]
12. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis. Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327 [TBL] [Abstract][Full Text] [Related]
13. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490 [TBL] [Abstract][Full Text] [Related]
14. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436 [TBL] [Abstract][Full Text] [Related]
15. Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis. Jiang X; Huang Y; Wang X; Liang Q; Li Y; Li F; Fu X; Huang C; Liu H Biomed Pharmacother; 2017 Jul; 91():1065-1074. PubMed ID: 28525947 [TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Li J; Huang S; Armstrong EA; Fowler JF; Harari PM Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810 [TBL] [Abstract][Full Text] [Related]
17. Pseudogene MAPK6P4-encoded functional peptide promotes glioblastoma vasculogenic mimicry development. Zhang M; Zhao Y; Liu X; Ruan X; Wang P; Liu L; Wang D; Dong W; Yang C; Xue Y Commun Biol; 2023 Oct; 6(1):1059. PubMed ID: 37853052 [TBL] [Abstract][Full Text] [Related]
18. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294 [TBL] [Abstract][Full Text] [Related]
19. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling. Ma Q; Chen W; Chen W Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645 [TBL] [Abstract][Full Text] [Related]
20. ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling. Chen L; Xie X; Wang T; Xu L; Zhai Z; Wu H; Deng L; Lu Q; Chen Z; Yang X; Lu H; Chen YG; Luo S Neuro Oncol; 2023 May; 25(5):871-885. PubMed ID: 36322624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]